New Zealand markets closed

ICPT Jan 2025 30.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.80000.0000 (0.00%)
As of 10:05AM EDT. Market open.
Full screen
Previous close0.8000
Expiry date2025-01-17
Day's range0.8000 - 0.8000
Contract rangeN/A
Open interest74
  • Motley Fool

    Why CymaBay Therapeutics Stock Is Jumping Today

    The continued momentum is a result of CymaBay's announcement yesterday of positive top-line results from a late-stage clinical study evaluating experimental drug seladelpar in treating primary biliary cholangitis (PBC), a rare chronic inflammatory liver disease. The great news for CymaBay, though, is that seladelpar appears to have a key advantage over those other PBC treatments. The results from the company's phase 3 study found that it significantly reduced itching, which is a major issue for many PBC patients.

  • Zacks

    Why Is Fate Therapeutics (FATE) Down 23.5% Since Last Earnings Report?

    Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire

    Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences

    MORRISTOWN, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that Jerry Durso, President and Chief Executive Officer of Intercept, and Andrew Saik, Chief Financial Officer of Intercept, will participate in fireside chats and investor meetings at the following upcoming investor conferences: The H.C. Wai